WebMD (blog)What are the “Blood Cancers?”WebMD (blog)Treatments may range from observation to well-tolerated immune therapies (such as rituximab, which has revolutionized the treatment of NHL) to intensive chemotherapy and even a stem-cell transpla…
Hot Off the Press: Dr. Lapp's Latest ME LetterProHealthRead it to find out about: • An upcoming meeting of the Open Medicine Institute team to formulate plans for 2012 (including how their clinics will participate in OMI studies, such as, hopeful…
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected …EON: Enhanced Online News (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVA…
Inotuzumab Ozogamicin Achieves 'Markedly Long' Antitumor Response in Indolent …Cancer NetworkInotuzumab ozogamicin was administered 1.8 mg/m 2 intravenously once every 28 days for a planned 4 to 8 cycles to patients whose indolent B-cell NHL …
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected …Genetic Engineering NewsThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the…
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on …
VIDEO: 3-Segment ME/CFS Alert Interview with Dr. Kogelnik at Open Medicine …ProHealthThe OMI is already managing 1000-some ME/CFS/FM patients, and actively identifying and directing trials of novel, high-tech diagnostic and treatment ideas (such as a…
The Oncology ReportSlowed Infusions Cut Hypersensitivity Reactions in Rituximab DesensitizationThe Oncology ReportORLANDO – A slowed, rate-controlled infusion of rituximab during a desensitization protocol significantly reduced the number of hypersen…
NMSS reports clinical trial alert in Bradenton, FL and other cities nationwideExaminer.comThe National Multiple Sclerosis Society (NMSS) announced a trial alert yesterday for the study of daclizumab high yield process (DAC HYP). The alert stated the st…
Matlock TodayPenny's planned a year of fund-raisingMatlock TodayPenny has received her second treatment of Rituximab and her condition was already showing some small signs of stabilising. “I am so grateful for the kindness and generosity of every…